Literature DB >> 6737077

Tc-99m galactosyl-neoglycoalbumin: in vitro characterization of receptor-mediated binding.

D R Vera, K A Krohn, R C Stadalnik, P O Scheibe.   

Abstract

Hepatic binding protein (HBP) is a membrane receptor that binds and transports plasma glycoproteins from hepatic blood to hepatocellular lysosomes. We have characterized the in vitro binding of Tc-99m galactosyl-neoglycoalbumin (Tc-NGA), a synthetic HBP ligand, to liver membrane. Structural modifications of NGA resulted in the alteration of the equilibrium constant, KA, and the forward-binding rate constant, kb. Binding was second-order; the relative amount of membrane-bound NGA depended on the initial concentrations of ligand and membrane. Membrane displacement studies, using carrier ligands in contrast to previously bound Tc-NGA or I-NGA, correlated with the binding characteristics of a native HBP ligand, asialo-orosomucoid. We used computer simulation to study the detectability of the changes in HBP concentration at different values of kb. The simulations indicated that radiopharmacokinetic sensitivity to alterations in [HBP] should be possible using a neoglycoalbumin preparation with a carbohydrate density within the range of 15 to 25 galactose units per albumin molecule.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6737077

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  19 in total

1.  Lactosamination of liposomes and hepatotropic targeting research.

Authors:  Yong-Peng Chen; Lian Zhang; Qiao-Sheng Lu; Xiao-Rong Feng; Kang-Xian Luo
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 2.  Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery.

Authors:  D K Meijer; P van der Sluijs
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

3.  Functional hepatic imaging with receptor-binding radiopharmaceutical: clinical potential as a measure of functioning hepatocyte mass.

Authors:  M Kudo; A Todo; K Ikekubo; M Hino; Y Yonekura; K Yamamoto; K Torizuka
Journal:  Gastroenterol Jpn       Date:  1991-12

4.  Perioperative hepatic functional risk assessed with technetium-99m diethylenetriamine pentaacetic acid-galactosyl human serum albumin liver scintigraphy in patients undergoing pancreaticoduodenectomy complicated by obstructive jaundice.

Authors:  H Nakano; K Kumada; Y Takekuma; S Hasebe; Y Yoshizawa; M Yamaguchi; D Jaeck
Journal:  Int J Pancreatol       Date:  1999-02

5.  Impaired hepatic function in segmental biliary obstruction demonstrated with a receptor-binding radiotracer.

Authors:  Y Inoue; K Machida; N Honda; T Mamiya; T Takahashi; T Kamano; Y Sasaki
Journal:  Ann Nucl Med       Date:  1994-08       Impact factor: 2.668

6.  γ-Tilmanocept, a New Radiopharmaceutical Tracer for Cancer Sentinel Lymph Nodes, Binds to the Mannose Receptor (CD206).

Authors:  Abul K Azad; Murugesan V S Rajaram; Wendy L Metz; Frederick O Cope; Michael S Blue; David R Vera; Larry S Schlesinger
Journal:  J Immunol       Date:  2015-07-22       Impact factor: 5.422

7.  Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting.

Authors:  M Nishikawa; A Kamijo; T Fujita; Y Takakura; H Sezaki; M Hashida
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

8.  A new liver functional study using Tc-99m DTPA-galactosyl human serum albumin: evaluation of the validity of several functional parameters.

Authors:  K Koizumi; G Uchiyama; T Arai; T Ainoda; Y Yoda
Journal:  Ann Nucl Med       Date:  1992-05       Impact factor: 2.668

9.  99mTc-neoglycoalbumin (NGA)-binding to human hepatic binding protein (HBP) in vitro.

Authors:  I Virgolini; P Angelberger; C Müller; J O'Grady; H Sinzinger
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

10.  Development of ⁶⁸Ga-labelled DTPA galactosyl human serum albumin for liver function imaging.

Authors:  Roland Haubner; David R Vera; Salman Farshchi-Heydari; Anna Helbok; Christine Rangger; Daniel Putzer; Irene J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.